Company Overview of Frazier Healthcare Ventures
Frazier Healthcare Ventures is a private equity and venture capital firm specializing in growth equity financing; incubation; expansion stage equity; recapitalizations; leveraged recapitalizations; buyouts; spinouts; shareholder liquidity; startups, early stage investments including seed and Series A and B financing rounds; late stage investments including Series C, D, mid venture, middle market, bridge financing, and PIPEs investments; and de novo investments across all stages of a company’s development. It seeks to invest in the biopharmaceutical, pharmaceutical services, biotechnology, life science, healthcare information technology, medical device, specialty distribution, medical produ...
Two Union Square
601 Union Street
Seattle, WA 98101
Founded in 1991
Key Executives for Frazier Healthcare Ventures
Managing Partner and Founder
Chief Financial Officer and Partner
General Partner and Founding General Partner
Compensation as of Fiscal Year 2015.
Frazier Healthcare Ventures Key Developments
Tadataka Yamada Re-Joins the Frazier Healthcare to Serve as a Venture Partner on the Life Sciences Team
Jul 6 15
Frazier Healthcare announced that Tadataka Yamada, Ph.D. has re-joined the firm. He will serve as a Venture Partner on the Life Sciences team, focusing on creating companies as well as providing strategic guidance to existing portfolio companies. He will also serve as a Senior Advisor to the Growth Buyout team, where he will provide advice on opportunities in pharmaceutical services and spin-outs from large healthcare companies, and sit on boards of portfolio companies such as PCI, a large pharmaceutical services company in the Frazier portfolio. Before re-joining Frazier, Dr. Yamada was Chief Medical and Scientific Officer at Takeda Pharmaceuticals in Tokyo, as well as a member of the Board of Directors. In addition to his role at Frazier, Dr. Yamada serves as a member of the board of directors at the Clinton Health Access Initiative and of the Council of the Institute of Medicine of the National Academy of Sciences.
Frazier Healthcare Adds Chris Karkenny to Growth Buyout Team as an Operating Partner
Apr 20 15
Frazier Healthcare reported that Chris Karkenny has joined Frazier's Growth Buyout team as an Operating Partner. Karkenny will work with the Growth Buyout team in identifying investment opportunities in the healthcare services space and other related healthcare sectors. The company reported that Karkenny has over 25 years of experience managing high growth environments, completing repositioning, restructurings and consolidations, and executing turnarounds to maximize shareholder value in both public and private companies. According to a release, prior to joining Frazier, Karkenny served as Executive Vice President and Chief Financial Officer at Apria Healthcare.
Richard E. Maroun, Esq. Joins Frazier Healthcare as an Operating Executive
Apr 2 15
Frazier Healthcare announced that Richard E. Maroun, Esq., has joined the firm as an Operating Executive on the Growth Buyout team. Most recently, Mr. Maroun was Senior Vice President and General Counsel of Aptalis Pharma. He has served in numerous senior roles for APP Pharmaceuticals -- as Executive Vice President, Chief Administrative Officer, General Counsel, and Business Development Officer.
Similar Private Companies By Industry
Recent Private Companies Transactions